A novel serum m7G-harboring microRNA signature for cancer detection

Yaxin Chen,Yufang Xie,Liyun Bi,Hang Ci,Weimin Li,Dan Liu

DOI: https://doi.org/10.3389/fgene.2024.1270302

IF: 3.7

2024-02-07

Frontiers in Genetics

Abstract:Background: Emerging evidence points to the exceptional importance and value of m 7 G alteration in the diagnosis and prognosis of cancers. Nonetheless, a biomarker for precise screening of various cancer types has not yet been developed based on serum m 7 G-harboring miRNAs. Methods: A total of 20,702 serum samples, covering 12 cancer types and consisting of 7,768 cancer samples and 12,934 cancer-free samples were used in this study. A m 7 G target miRNA diagnostic signature (m 7 G-miRDS) was established through the least absolute shrinkage and selection operator (LASSO) analyses in a training dataset ( n = 10,351), and validated in a validation dataset ( n = 10,351). Results: The m 7 G-miRDS model, a 12 m 7 G-target-miRNAs signature, demonstrated high accuracy and was qualified for cancer detection. In the training and validation cohort, the area under the curve (AUC) reached 0.974 (95% CI 0.971–0.977) and 0.972 (95% CI 0.969–0.975), respectively. The m 7 G-miRDS showed superior sensitivity in each cancer type and had a satisfactory AUC in identifying bladder cancer, lung cancer and esophageal cancer. Additionally, the diagnostic performance of m 7 G-miRDS was not interfered by the gender, age and benign disease. Conclusion: Our results greatly extended the value of serum circulating miRNAs and m 7 G in cancer detection, and provided a new direction and strategy for the development of novel biomarkers with high accuracy, low cost and less invasiveness for mass cancer screening, such as ncRNA modification.

genetics & heredity